Astrazeneca PLC AZN
Astrazeneca PLC (NYSE: AZN) is an oncology drug developer. Its lead program, Marketed portfolio (e.g., Farxiga, Tagrisso, Imfinzi, Enhertu), is in Phase 3 for oncology, CVRM, respiratory & immunology, rare disease. Its next catalyst on record is camizestrant CAMBRIA-1: Phase III data readout (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: camizestrant CAMBRIA-1 — Phase III data readout (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Tagrisso (osimertinib) | EGFRm NSCLC | small molecule | Approved |
| Farxiga/Forxiga (dapagliflozin) | T2D, heart failure, CKD | small molecule | Approved |
| Imfinzi (durvalumab) | multiple cancers (NSCLC, SCLC, BTC, HCC, bladder, gastric, endometrial) | antibody | Approved |
| Enhertu (trastuzumab deruxtecan; partnered) | HER2+ breast, gastric, NSCLC, tumour-agnostic | antibody | Approved |
| Calquence (acalabrutinib) | CLL, MCL | small molecule | Approved |
| Lynparza (olaparib; partnered) | ovarian, breast, pancreatic, prostate cancers | small molecule | Approved |
| Fasenra (benralizumab) | severe eosinophilic asthma, EGPA | antibody | Approved |
| Brilinta/Brilique (ticagrelor) | ACS / MI | small molecule | Approved |
| Datroway (datopotamab deruxtecan; partnered) | HR+/HER2- breast cancer, EGFRm NSCLC | antibody | Approved |
| Saphnelo (anifrolumab) | systemic lupus erythematosus | antibody | Approved |
| camizestrant (SERENA-6 and SERENA-4) | HR+ HER2- breast cancer | small molecule | Phase 3 |
| baxdrostat (BaxHTN/Bax24/BaxAsia) | hypertension | small molecule | Phase 3 |
Recent results and decisions
- Oct 30, 2026met VOLGA Phase III trial showed perioperative Imfinzi plus enfortumab vedotin reduced the risk of progression or death by 49% versus radical cystectomy in MIBC patients ineligible for cisplatin.
Positive results from a planned interim analysis of the VOLGA Phase III trial showed perioperative Imfinzi plus neoadjuvant enfortumab vedotin reduced the risk of disease progression, recurrence, not undergoing surgery or death by 49% versus radical cystectomy (EFS HR 0.51; 95% CI 0.38-0.67; p<0.000
Filing - Oct 30, 2026met CLARITY-Gastric01 Phase III trial showed sonesitatug vedotin reduced the risk of death by 53% versus investigator's choice in 3rd-line CLDN18.2-positive gastric/GEJ/oesophageal adenocarcinoma.
Positive results from a planned interim analysis of the CLARITY-Gastric01 Phase III trial showed sonesitatug vedotin reduced the risk of death by 53% versus investigator's choice of therapy (HR 0.47; 95% CI 0.36-0.62; p<0.001) in patients with 3rd- and later-line CLDN18.2-positive advanced gastric,
Filing - Oct 30, 2026approval Datroway received China approval for patients with unresectable or metastatic TNBC not candidates for PD-1/PD-L1 inhibitor therapy.
For patients with unresectable or metastatic TNBC not candidates for PD-1/PD-L1 inhibitor therapy.
Filing
107 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
- Summit Therapeutics Inc. SMMT
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.